Price
$2.9
Decreased by -0.07%
Dollar Volume (20D)
3.00 M
ADR%
12.12
Earnings Report Date (estimate)
May 4, 23 (0.22)
Market Cap.
501.92 M
Shares Float
67.28 M
Shares Outstanding
173.08 M
Beta
1.58
Price / Earnings
-2.07
BPR
248.80
20D Range
1.79 3.45
50D Range
1.61 3.45
200D Range
1.60 3.77
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
May 4, 23 -0.23
Increased by +43.90%
-0.27
Increased by +54.87%
Mar 7, 23 -0.23
Increased by +54.90%
-0.27
Increased by +54.87%
Nov 3, 22 -0.47
Increased by 0.00%
-0.46
Decreased by -4.73%
Aug 4, 22 -0.46
Increased by +2.13%
-0.42
Decreased by -22.68%
May 5, 22 -0.41
Increased by +21.15%
-0.48
Increased by +30.38%
Mar 10, 22 -0.51
Increased by +38.55%
-0.46
Decreased by -23.63%
Nov 3, 21 -0.47
Increased by +34.72%
-0.51
Increased by +15.38%
Aug 5, 21 -0.47
Increased by +24.19%
-0.50
Increased by +12.00%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Mar 31, 23 1.29 M
Increased by +N/A%
-39.81 M
Decreased by -7.42%
Decreased by -3.08 K%
Decreased by N/A%
Dec 31, 22 3.83 M
Increased by +364.76%
-26.95 M
Increased by +35.32%
Decreased by -704.60%
Increased by +86.08%
Sep 30, 22 2.37 M
Increased by +N/A%
-42.77 M
Decreased by -25.82%
Decreased by -1.81 K%
Decreased by N/A%
Jun 30, 22 0.00
Decreased by -100.00%
-42.06 M
Decreased by -26.79%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0.00
Decreased by -100.00%
-37.06 M
Decreased by -11.41%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 823.00 K
Increased by +N/A%
-41.67 M
Increased by +2.79%
Decreased by -5.06 K%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by -100.00%
-33.99 M
Increased by +8.91%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 1.51 M
Increased by +414.33%
-33.17 M
Decreased by -3.52%
Decreased by -2.20 K%
Increased by +79.87%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.